{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T02:22:11Z","timestamp":1793586131014,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41575-022-00687-7","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T12:15:56Z","timestamp":1666959356000},"page":"26-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Mechanisms of pruritus in cholestasis: understanding and treating the itch"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5114-7799","authenticated-orcid":false,"given":"Ulrich","family":"Beuers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald P. J.","family":"Oude Elferink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"687_CR1","unstructured":"Alighieri, D. La Divina Commedia - I. Inferno Canto XXIX (1307\u20131321)."},{"key":"687_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver.","year":"2009","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 51, 237\u2013267 (2009).","journal-title":"J. Hepatol."},{"key":"687_CR3","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2165\/00003495-200868150-00006","volume":"68","author":"AE Kremer","year":"2008","unstructured":"Kremer, A. E., Beuers, U., Oude-Elferink, R. P. & Pusl, T. Pathogenesis and treatment of pruritus in cholestasis. Drugs 68, 2163\u20132182 (2008).","journal-title":"Drugs"},{"key":"687_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sder.2011.04.009","volume":"30","author":"NV Bergasa","year":"2011","unstructured":"Bergasa, N. V. The itch of liver disease. Semin. Cutan. Med. Surg. 30, 93\u201398 (2011).","journal-title":"Semin. Cutan. Med. Surg."},{"key":"687_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.26909","volume":"60","author":"U Beuers","year":"2014","unstructured":"Beuers, U., Kremer, A. E., Bolier, R. & Elferink, R. P. Pruritus in cholestasis: facts and fiction. Hepatology 60, 399\u2013407 (2014).","journal-title":"Hepatology"},{"key":"687_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver.","year":"2017","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67, 145\u2013172 (2017).","journal-title":"J. Hepatol."},{"key":"687_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-022-07581-x","author":"MJ Mayo","year":"2022","unstructured":"Mayo, M. J. et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig. Dis. Sci. https:\/\/doi.org\/10.1007\/s10620-022-07581-x (2022).","journal-title":"Dig. Dis. Sci."},{"key":"687_CR8","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1111\/liv.15271","volume":"42","author":"KN van Munster","year":"2022","unstructured":"van Munster, K. N., Dijkgraaf, M. G. W., Oude Elferink, R. P. J., Beuers, U. & Ponsioen, C. Y. Symptom patterns in the daily life of PSC patients. Liver Int. 42, 1562\u20131570 (2022).","journal-title":"Liver Int."},{"key":"687_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1258\/om.2010.090055","volume":"3","author":"AP Kenyon","year":"2010","unstructured":"Kenyon, A. P. et al. Pruritus in pregnancy: a study of anatomical distribution and prevalence in relation to the development of obstetric cholestasis. Obstet. Med. 3, 25\u201329 (2010).","journal-title":"Obstet. Med."},{"key":"687_CR10","first-page":"1258","volume":"92","author":"NT McPhedran","year":"1965","unstructured":"McPhedran, N. T. & Henderson, R. D. Pruritus and Jaundice. Can. Med. Assoc. J. 92, 1258\u20131260 (1965).","journal-title":"Can. Med. Assoc. J."},{"key":"687_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","volume":"73","author":"R Loomba","year":"2021","unstructured":"Loomba, R. et al. Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH. Hepatology 73, 625\u2013643 (2021).","journal-title":"Hepatology"},{"key":"687_CR12","doi-asserted-by":"publisher","first-page":"639674","DOI":"10.3389\/fmed.2021.639674","volume":"8","author":"J Langedijk","year":"2021","unstructured":"Langedijk, J., Beuers, U. H. & Oude Elferink, R. P. J. Cholestasis-associated pruritus and its pruritogens. Front. Med. 8, 639674 (2021).","journal-title":"Front. Med."},{"key":"687_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbadis.2014.02.007","volume":"1842","author":"AE Kremer","year":"2014","unstructured":"Kremer, A. E., Feramisco, J., Reeh, P. W., Beuers, U. & Oude Elferink, R. P. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochim. Biophys. Acta 1842, 869\u2013892 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"687_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1152\/physrev.00049.2019","volume":"101","author":"A Perino","year":"2021","unstructured":"Perino, A., Demagny, H., Velazquez-Villegas, L. & Schoonjans, K. Molecular physiology of bile acid signaling in health, disease, and aging. Physiol. Rev. 101, 683\u2013731 (2021).","journal-title":"Physiol. Rev."},{"key":"687_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/164_2019_238","volume":"256","author":"S Fiorucci","year":"2019","unstructured":"Fiorucci, S. & Distrutti, E. The pharmacology of bile acids and their receptors. Handb. Exp. Pharmacol. 256, 3\u201318 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"key":"687_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","volume":"139","author":"AE Kremer","year":"2010","unstructured":"Kremer, A. E. et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 139, 1008\u20131018 (2010).","journal-title":"Gastroenterology"},{"key":"687_CR17","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0016-5085(19)31870-0","volume":"73","author":"CN Ghent","year":"1977","unstructured":"Ghent, C. N., Bloomer, J. R. & Klatskin, G. Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus. Gastroenterology 73, 1125\u20131130 (1977).","journal-title":"Gastroenterology"},{"key":"687_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1172\/JCI64551","volume":"123","author":"F Alemi","year":"2013","unstructured":"Alemi, F. et al. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest. 123, 1513\u20131530 (2013).","journal-title":"J. Clin. Invest."},{"key":"687_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.48431","volume":"8","author":"H Yu","year":"2019","unstructured":"Yu, H. et al. MRGPRX4 is a bile acid receptor for human cholestatic itch. eLife 8, e48431 (2019).","journal-title":"eLife"},{"key":"687_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","volume":"160","author":"E de Vries","year":"2021","unstructured":"de Vries, E. et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, Placebo-controlled trial. Gastroenterology 160, 734\u2013743 (2021).","journal-title":"Gastroenterology"},{"key":"687_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/hep.1840150409","volume":"15","author":"U Beuers","year":"1992","unstructured":"Beuers, U. et al. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 15, 603\u2013608 (1992).","journal-title":"Hepatology"},{"key":"687_CR22","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1126\/science.1360704","volume":"258","author":"SP Cole","year":"1992","unstructured":"Cole, S. P. et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650\u20131654 (1992).","journal-title":"Science"},{"key":"687_CR23","doi-asserted-by":"publisher","first-page":"10525","DOI":"10.1073\/pnas.1903316116","volume":"116","author":"J Meixiong","year":"2019","unstructured":"Meixiong, J., Vasavda, C., Snyder, S. H. & Dong, X. MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus. Proc. Natl Acad. Sci. USA 116, 10525\u201310530 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"687_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms, M. H. et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J. Hepatol. 71, 357\u2013365 (2019).","journal-title":"J. Hepatol."},{"key":"687_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1046\/j.1365-2036.2003.01792.x","volume":"18","author":"W Hempfling","year":"2003","unstructured":"Hempfling, W., Dilger, K. & Beuers, U. Systematic review: ursodeoxycholic acid \u2014 adverse effects and drug interactions. Aliment. Pharmacol. Ther. 18, 963\u2013972 (2003).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"687_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","volume":"57","author":"K Dilger","year":"2012","unstructured":"Dilger, K. et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J. Hepatol. 57, 133\u2013140 (2012).","journal-title":"J. Hepatol."},{"key":"687_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85660-1","volume":"11","author":"J Langedijk","year":"2021","unstructured":"Langedijk, J. et al. Reduced spontaneous itch in mouse models of cholestasis. Sci. Rep. 11, 6127 (2021).","journal-title":"Sci. Rep."},{"key":"687_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129866","volume":"10","author":"S Cipriani","year":"2015","unstructured":"Cipriani, S. et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS ONE 10, e0129866 (2015).","journal-title":"PLoS ONE"},{"key":"687_CR29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","volume":"147","author":"T Lieu","year":"2014","unstructured":"Lieu, T. et al. The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice. Gastroenterology 147, 1417\u20131428 (2014).","journal-title":"Gastroenterology"},{"key":"687_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.biopha.2016.10.068","volume":"84","author":"S Ostadhadi","year":"2016","unstructured":"Ostadhadi, S. et al. Evidence for the involvement of nitric oxide in cholestasis-induced itch associated response in mice. Biomed. Pharmacother. 84, 1367\u20131374 (2016).","journal-title":"Biomed. Pharmacother."},{"key":"687_CR31","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/cphy.c120027","volume":"3","author":"JL Boyer","year":"2013","unstructured":"Boyer, J. L. Bile formation and secretion. Compr. Physiol. 3, 1035\u20131078 (2013).","journal-title":"Compr. Physiol."},{"key":"687_CR32","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."},{"key":"687_CR33","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/17474124.2020.1748498","volume":"14","author":"RA Shah","year":"2020","unstructured":"Shah, R. A. & Kowdley, K. V. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 14, 311\u2013321 (2020).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"687_CR34","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956\u2013965 (2015).","journal-title":"Lancet"},{"key":"687_CR35","first-page":"1449","volume":"18","author":"S Fiorucci","year":"2014","unstructured":"Fiorucci, S. et al. Targeting FXR in cholestasis: hype or hope. Expert Opin. Ther. Targets 18, 1449\u20131459 (2014).","journal-title":"Expert Opin. Ther. Targets"},{"key":"687_CR36","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner, M. et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology 70, 788\u2013801 (2019).","journal-title":"Hepatology"},{"key":"687_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/164_2019_232","volume":"256","author":"C Gege","year":"2019","unstructured":"Gege, C., Hambruch, E., Hambruch, N., Kinzel, O. & Kremoser, C. Nonsteroidal FXR ligands: current status and clinical applications. Handb. Exp. Pharmacol. 256, 167\u2013205 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"key":"687_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","volume":"75","author":"C Kremoser","year":"2021","unstructured":"Kremoser, C. FXR agonists for NASH: How are they different and what difference do they make? J. Hepatol. 75, 12\u201315 (2021).","journal-title":"J. Hepatol."},{"key":"687_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13608","author":"R Erken","year":"2021","unstructured":"Erken, R. et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study. J. Viral Hepat. https:\/\/doi.org\/10.1111\/jvh.13608 (2021).","journal-title":"J. Viral Hepat."},{"key":"687_CR40","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/hep.23821","volume":"52","author":"EM Kuiper","year":"2010","unstructured":"Kuiper, E. M. et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52, 1334\u20131340 (2010).","journal-title":"Hepatology"},{"key":"687_CR41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/hep.27240","volume":"61","author":"FM Vaz","year":"2015","unstructured":"Vaz, F. M. et al. Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype. Hepatology 61, 260\u2013267 (2015).","journal-title":"Hepatology"},{"key":"687_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10545-017-0031-9","volume":"40","author":"F Van Herpe","year":"2017","unstructured":"Van Herpe, F. et al. NTCP deficiency and persistently raised bile salts: an adult case. J. Inherit. Metab. Dis. 40, 313\u2013315 (2017).","journal-title":"J. Inherit. Metab. Dis."},{"key":"687_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017305","volume":"98","author":"C Dong","year":"2019","unstructured":"Dong, C. et al. Clinical and histopathologic features of sodium taurocholate cotransporting polypeptide deficiency in pediatric patients. Medicine 98, e17305 (2019).","journal-title":"Medicine"},{"key":"687_CR44","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.21037\/tp-20-360","volume":"10","author":"TT Zou","year":"2021","unstructured":"Zou, T. T., Zhu, Y., Wan, C. M. & Liao, Q. Clinical features of sodium-taurocholate cotransporting polypeptide deficiency in pediatric patients: case series and literature review. Transl. Pediatr. 10, 1045\u20131054 (2021).","journal-title":"Transl. Pediatr."},{"key":"687_CR45","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.clinre.2014.07.011","volume":"39","author":"S Erlinger","year":"2015","unstructured":"Erlinger, S. NTCP deficiency: a new inherited disease of bile acid transport. Clin. Res. Hepatol. Gastroenterol. 39, 7\u20138 (2015).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"687_CR46","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44116","author":"J Meixiong","year":"2019","unstructured":"Meixiong, J. et al. Identification of a bilirubin receptor that may mediate a component of cholestatic itch. eLlife https:\/\/doi.org\/10.7554\/eLife.44116 (2019).","journal-title":"eLlife"},{"key":"687_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jhep.2009.11.012","volume":"52","author":"JM Stapelbroek","year":"2010","unstructured":"Stapelbroek, J. M., van Erpecum, K. J., Klomp, L. W. & Houwen, R. H. Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol. 52, 258\u2013271 (2010).","journal-title":"J. Hepatol."},{"key":"687_CR48","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1111\/liv.15239","volume":"42","author":"SJ Aronson","year":"2022","unstructured":"Aronson, S. J. et al. Disease burden and management of Crigler-Najjar syndrome: report of a world registry. Liver Int. 42, 1593\u20131604 (2022).","journal-title":"Liver Int."},{"key":"687_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3109\/07853890009011758","volume":"32","author":"H Reyes","year":"2000","unstructured":"Reyes, H. & Sjovall, J. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy. Ann. Med. 32, 94\u2013106 (2000).","journal-title":"Ann. Med."},{"key":"687_CR50","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/hep.28365","volume":"63","author":"H Reyes","year":"2016","unstructured":"Reyes, H. Sulfated progesterone metabolites in the pathogenesis of intrahepatic cholestasis of pregnancy: another loop in the ascending spiral of medical knowledge. Hepatology 63, 1080\u20131082 (2016).","journal-title":"Hepatology"},{"key":"687_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159203","volume":"11","author":"A Parizek","year":"2016","unstructured":"Parizek, A. et al. A comprehensive evaluation of steroid metabolism in women with intrahepatic cholestasis of pregnancy. PLoS ONE 11, e0159203 (2016).","journal-title":"PLoS ONE"},{"key":"687_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28265","author":"S Abu-Hayyeh","year":"2016","unstructured":"Abu-Hayyeh, S. et al. Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology https:\/\/doi.org\/10.1002\/hep.28265 (2016).","journal-title":"Hepatology"},{"key":"687_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000078632","volume":"72","author":"T Hashimoto","year":"2004","unstructured":"Hashimoto, T., Ohata, H. & Momose, K. Itch-scratch responses induced by lysophosphatidic acid in mice. Pharmacology 72, 51\u201356 (2004).","journal-title":"Pharmacology"},{"key":"687_CR54","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1128\/MCB.02419-05","volume":"26","author":"LA van Meeteren","year":"2006","unstructured":"van Meeteren, L. A. et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol. Cell Biol. 26, 5015\u20135022 (2006).","journal-title":"Mol. Cell Biol."},{"key":"687_CR55","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hep.25748","volume":"56","author":"AE Kremer","year":"2012","unstructured":"Kremer, A. E. et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56, 1391\u20131400 (2012).","journal-title":"Hepatology"},{"key":"687_CR56","doi-asserted-by":"publisher","first-page":"166239","DOI":"10.1016\/j.bbadis.2021.166239","volume":"1867","author":"J Langedijk","year":"2021","unstructured":"Langedijk, J. et al. Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166239 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"687_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11248","volume":"7","author":"WJ Keune","year":"2016","unstructured":"Keune, W. J. et al. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling. Nat. Commun. 7, 11248 (2016).","journal-title":"Nat. Commun."},{"key":"687_CR58","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1194\/jlr.M057661","volume":"56","author":"MG Benesch","year":"2015","unstructured":"Benesch, M. G., Zhao, Y. Y., Curtis, J. M., McMullen, T. P. & Brindley, D. N. Regulation of autotaxin expression and secretion by lysophosphatidate and sphingosine 1-phosphate. J. Lipid Res. 56, 1134\u20131144 (2015).","journal-title":"J. Lipid Res."},{"key":"687_CR59","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jhep.2014.10.041","volume":"62","author":"AE Kremer","year":"2015","unstructured":"Kremer, A. E. et al. Autotaxin activity has a high accuracy to diagnose intrahepatic cholestasis of pregnancy. J. Hepatol. 62, 897\u2013904 (2015).","journal-title":"J. Hepatol."},{"key":"687_CR60","doi-asserted-by":"publisher","first-page":"10252","DOI":"10.1074\/jbc.M116.716464","volume":"291","author":"Y Chen","year":"2016","unstructured":"Chen, Y. et al. Transient receptor potential vanilloid 4 ion channel functions as a pruriceptor in epidermal keratinocytes to evoke histaminergic itch. J. Biol. Chem. 291, 10252\u201310262 (2016).","journal-title":"J. Biol. Chem."},{"key":"687_CR61","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1053\/j.gastro.2021.03.049","volume":"161","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. Gastroenterology 161, 301\u2013317 (2021).","journal-title":"Gastroenterology"},{"key":"687_CR62","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gene.2011.03.003","volume":"480","author":"X Li","year":"2011","unstructured":"Li, X. et al. MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene 480, 34\u201341 (2011).","journal-title":"Gene"},{"key":"687_CR63","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.neuron.2018.06.039","volume":"99","author":"Q Han","year":"2018","unstructured":"Han, Q. et al. miRNA-711 binds and activates TRPA1 extracellularly to evoke acute and chronic pruritus. Neuron 99, 449\u2013463.e6 (2018).","journal-title":"Neuron"},{"key":"687_CR64","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neuron.2014.02.011","volume":"82","author":"CK Park","year":"2014","unstructured":"Park, C. K. et al. Extracellular microRNAs activate nociceptor neurons to elicit pain via TLR7 and TRPA1. Neuron 82, 47\u201354 (2014).","journal-title":"Neuron"},{"key":"687_CR65","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","volume":"77","author":"European Association for the Study of the Liver","year":"2022","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis.J. Hepatol. 77, 761\u2013806 (2022).","journal-title":"J. Hepatol."},{"key":"687_CR66","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S0168-8278(97)80146-8","volume":"27","author":"J Palma","year":"1997","unstructured":"Palma, J. et al. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol. 27, 1022\u20131028 (1997).","journal-title":"J. Hepatol."},{"key":"687_CR67","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/hep.20952","volume":"42","author":"A Glantz","year":"2005","unstructured":"Glantz, A., Marschall, H. U., Lammert, F. & Mattsson, L. A. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. Hepatology 42, 1399\u20131405 (2005).","journal-title":"Hepatology"},{"key":"687_CR68","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","volume":"129","author":"J Kondrackiene","year":"2005","unstructured":"Kondrackiene, J., Beuers, U. & Kupcinskas, L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology 129, 894\u2013901 (2005).","journal-title":"Gastroenterology"},{"key":"687_CR69","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1053\/j.gastro.2012.08.004","volume":"143","author":"Y Bacq","year":"2012","unstructured":"Bacq, Y. et al. Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis. Gastroenterology 143, 1492\u20131501 (2012).","journal-title":"Gastroenterology"},{"key":"687_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000493.pub2","author":"V Gurung","year":"2013","unstructured":"Gurung, V., Middleton, P., Milan, S. J., Hague, W. & Thornton, J. G. Interventions for treating cholestasis in pregnancy. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD000493.pub2 (2013).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"Suppl. 1","key":"687_CR71","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers, U., Trauner, M., Jansen, P. & Poupon, R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J. Hepatol. 62 (Suppl. 1), 25\u201337 (2015).","journal-title":"J. Hepatol."},{"key":"687_CR72","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpgasthep0521","volume":"3","author":"U Beuers","year":"2006","unstructured":"Beuers, U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 318\u2013328 (2006).","journal-title":"Nat. Clin. Pract. Gastroenterol. Hepatol."},{"key":"687_CR73","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(19)31270-X","volume":"394","author":"LC Chappell","year":"2019","unstructured":"Chappell, L. C. et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet 394, 849\u2013860 (2019).","journal-title":"Lancet"},{"key":"687_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3799","volume":"344","author":"LC Chappell","year":"2012","unstructured":"Chappell, L. C. et al. Ursodeoxycholic acid versus placebo, and early term delivery versus expectant management, in women with intrahepatic cholestasis of pregnancy: semifactorial randomised clinical trial. BMJ 344, e3799 (2012).","journal-title":"BMJ"},{"key":"687_CR75","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jhep.2019.11.018","volume":"72","author":"U Beuers","year":"2020","unstructured":"Beuers, U. & de Vries, E. Reply to: \u201cUDCA therapy in intrahepatic cholestasis of pregnancy?\u201d. J. Hepatol. 72, 587\u2013588 (2020).","journal-title":"J. Hepatol."},{"key":"687_CR76","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/1471-0528.16669","volume":"128","author":"AL Mitchell","year":"2021","unstructured":"Mitchell, A. L. et al. Re-evaluating diagnostic thresholds for intrahepatic cholestasis of pregnancy: case-control and cohort study. BJOG 128, 1635\u20131644 (2021).","journal-title":"BJOG"},{"key":"687_CR77","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.jhep.2019.08.020","volume":"71","author":"E de Vries","year":"2019","unstructured":"de Vries, E. & Beuers, U. Ursodeoxycholic acid in pregnancy? J. Hepatol. 71, 1237\u20131245 (2019).","journal-title":"J. Hepatol."},{"key":"687_CR78","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2468-1253(21)00074-1","volume":"6","author":"C Ovadia","year":"2021","unstructured":"Ovadia, C. et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. Lancet Gastroenterol. Hepatol. 6, 547\u2013558 (2021).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"687_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejogrb.2015.03.020","volume":"189","author":"V Geenes","year":"2015","unstructured":"Geenes, V. et al. Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 189, 59\u201363 (2015).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"687_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-020-03481-y","volume":"21","author":"WM Hague","year":"2021","unstructured":"Hague, W. M. et al. A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial. BMC Pregnancy Childbirth 21, 51 (2021).","journal-title":"BMC Pregnancy Childbirth"},{"key":"687_CR81","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1365-2362.2000.00606.x","volume":"30","author":"C Rust","year":"2000","unstructured":"Rust, C. et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur. J. Clin. Invest. 30, 135\u2013139 (2000).","journal-title":"Eur. J. Clin. Invest."},{"key":"687_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.011","author":"European Association for the Study of the Liver.","year":"2022","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.011 (2022).","journal-title":"J. Hepatol."},{"key":"687_CR83","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/hep.22906","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor, K. D. et al. Primary biliary cirrhosis. Hepatology 50, 291\u2013308 (2009).","journal-title":"Hepatology"},{"key":"687_CR84","first-page":"489","volume":"32","author":"R Agrawal","year":"2019","unstructured":"Agrawal, R. et al. Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials. Ann. Gastroenterol. 32, 489\u2013497 (2019).","journal-title":"Ann. Gastroenterol."},{"key":"687_CR85","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/liv.12290","volume":"34","author":"S Lens","year":"2014","unstructured":"Lens, S., Leoz, M., Nazal, L., Bruguera, M. & Pares, A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int. 34, 197\u2013203 (2014).","journal-title":"Liver Int."},{"key":"687_CR86","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ajg.2017.287","volume":"113","author":"A Reig","year":"2018","unstructured":"Reig, A., Sese, P. & Pares, A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am. J. Gastroenterol. 113, 49\u201355 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"687_CR87","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot, C. et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N. Engl. J. Med. 378, 2171\u20132181 (2018).","journal-title":"N. Engl. J. Med."},{"key":"687_CR88","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000450988","volume":"35","author":"VS Hegade","year":"2017","unstructured":"Hegade, V. S., Jones, D. E. & Hirschfield, G. M. Apical sodium-dependent transporter inhibitors in primary biliary cholangitis and primary sclerosing cholangitis. Dig. Dis. 35, 267\u2013274 (2017).","journal-title":"Dig. Dis."},{"key":"687_CR89","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","volume":"389","author":"VS Hegade","year":"2017","unstructured":"Hegade, V. S. et al. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet 389, 1114\u20131123 (2017).","journal-title":"Lancet"},{"key":"687_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25214-0","volume":"8","author":"S Al-Dury","year":"2018","unstructured":"Al-Dury, S. et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci. Rep. 8, 6658 (2018).","journal-title":"Sci. Rep."},{"key":"687_CR91","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1111\/liv.14553","volume":"40","author":"BM Kamath","year":"2020","unstructured":"Kamath, B. M., Stein, P., Houwen, R. H. J. & Verkade, H. J. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 40, 1812\u20131822 (2020).","journal-title":"Liver Int."},{"key":"687_CR92","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","volume":"398","author":"E Gonzales","year":"2021","unstructured":"Gonzales, E. et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet 398, 1581\u20131592 (2021).","journal-title":"Lancet"},{"key":"687_CR93","doi-asserted-by":"publisher","first-page":"101751","DOI":"10.1016\/j.clinre.2021.101751","volume":"45","author":"U Baumann","year":"2021","unstructured":"Baumann, U. et al. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: phase 2 study. Clin. Res. Hepatol. Gastroenterol. 45, 101751 (2021).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"687_CR94","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1111\/hepr.12830","volume":"47","author":"H Kumada","year":"2017","unstructured":"Kumada, H. et al. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: a randomized, double-blind trial. Hepatol. Res. 47, 972\u2013982 (2017).","journal-title":"Hepatol. Res."},{"key":"687_CR95","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s10620-020-06392-2","volume":"66","author":"RS Golpanian","year":"2021","unstructured":"Golpanian, R. S., Yosipovitch, G. & Levy, C. Use of butorphanol as treatment for cholestatic itch. Dig. Dis. Sci. 66, 1693\u20131699 (2021).","journal-title":"Dig. Dis. Sci."},{"key":"687_CR96","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/apt.13449","volume":"43","author":"VS Hegade","year":"2016","unstructured":"Hegade, V. S. et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment. Pharmacol. Ther. 43, 294\u2013302 (2016).","journal-title":"Aliment. Pharmacol. Ther."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00687-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00687-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T14:05:41Z","timestamp":1671804341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-022-00687-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1038\/s41575-022-00687-7","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"7 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}